In recent years, biological therapies have become increasingly used for the treatment of many conditions, specially inflammatory diseases. But they are expensive. Very expensive. To the rescue come the next generation of drugs: biosimilars. They are biologic medical products almost identical to the original product, but manufactured by a different company. The war of misinformation is served. How clinically relevant is the fact that almost identical is no really identical? The fear of the new is keeping thousands of patients away from very effective and safe therapies, and making some companies millions.